These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 27507055)

  • 1. Incidence and relative risk of hemorrhagic events associated with ramucirumab in cancer patients: a systematic review and meta-analysis.
    Tian R; Yan H; Zhang F; Sun P; Zheng X; Zhu Y; Wang Q; He J
    Oncotarget; 2016 Oct; 7(40):66182-66191. PubMed ID: 27507055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence and risk of hypertension associated with ramucirumab in cancer patients: A systematic review and meta-analysis.
    Qi WX; Fu S; Zhang Q; Guo XM
    J Cancer Res Ther; 2016; 12(2):775-81. PubMed ID: 27461650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hemorrhagic events in cancer patients treated with aflibercept: a meta-analysis.
    Peng L; Bu Z; Zhou Y; Ye X; Liu J; Zhao Q
    Tumour Biol; 2014 Sep; 35(9):9419-27. PubMed ID: 24957040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of cardiovascular adverse events in patients with solid tumors treated with ramucirumab: A meta analysis and summary of other VEGF targeted agents.
    Abdel-Rahman O; ElHalawani H
    Crit Rev Oncol Hematol; 2016 Jun; 102():89-100. PubMed ID: 27129437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of oral and gastrointestinal mucosal injury in patients with solid tumors treated with ramucirumab: a systematic review and meta-analysis.
    Abdel-Rahman O; ElHalawani H
    Expert Opin Drug Saf; 2015 Oct; 14(10):1495-506. PubMed ID: 26313327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of gastrointestinal perforation in cancer patients receiving ramucirumab: a meta-analysis of randomized controlled trials.
    Wang Z; Zhang J; Zhang L; Liu P; Xie Y; Zhou Q
    J Chemother; 2016 Aug; 28(4):328-34. PubMed ID: 26099278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence and risk of hemorrhagic events with vascular endothelial growth factor receptor tyrosine-kinase inhibitors: an up-to-date meta-analysis of 27 randomized controlled trials.
    Qi WX; Tang LN; Sun YJ; He AN; Lin F; Shen Z; Yao Y
    Ann Oncol; 2013 Dec; 24(12):2943-52. PubMed ID: 23921791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteinuria in Patients with Solid Tumors Treated with Ramucirumab: A Systematic Review and Meta-Analysis.
    Abdel-Rahman O; ElHalawani H
    Chemotherapy; 2014; 60(5-6):325-33. PubMed ID: 26302785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab.
    Arnold D; Fuchs CS; Tabernero J; Ohtsu A; Zhu AX; Garon EB; Mackey JR; Paz-Ares L; Baron AD; Okusaka T; Yoshino T; Yoon HH; Das M; Ferry D; Zhang Y; Lin Y; Binder P; Sashegyi A; Chau I
    Ann Oncol; 2017 Dec; 28(12):2932-2942. PubMed ID: 28950290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence and risk of cardiotoxicity in cancer patients treated with targeted therapies.
    Santoni M; Guerra F; Conti A; Lucarelli A; Rinaldi S; Belvederesi L; Capucci A; Berardi R
    Cancer Treat Rev; 2017 Sep; 59():123-131. PubMed ID: 28818671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of bleeding associated with antiangiogenic monoclonal antibodies bevacizumab and ramucirumab: a meta-analysis of 85 randomized controlled trials.
    Xiao B; Wang W; Zhang D
    Onco Targets Ther; 2018; 11():5059-5074. PubMed ID: 30174444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of hematological toxicities in patients with solid tumors treated with ramucirumab: a meta-analysis.
    Abdel-Rahman O; ElHalawani H
    Future Oncol; 2015; 11(21):2949-61. PubMed ID: 26422782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of high-grade bleeding in patients with cancer treated with bevacizumab: a meta-analysis of randomized controlled trials.
    Hang XF; Xu WS; Wang JX; Wang L; Xin HG; Zhang RQ; Ni W
    Eur J Clin Pharmacol; 2011 Jun; 67(6):613-23. PubMed ID: 21243343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased risk of serious hemorrhage with bevacizumab in cancer patients: a meta-analysis.
    Hapani S; Sher A; Chu D; Wu S
    Oncology; 2010; 79(1-2):27-38. PubMed ID: 21051914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ramucirumab Safety in East Asian Patients: A Meta-Analysis of Six Global, Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trials.
    Yen CJ; Muro K; Kim TW; Kudo M; Shih JY; Lee KW; Chao Y; Kim SW; Yamazaki K; Sohn J; Cheng R; Zhang Y; Binder P; Mi G; Orlando M; Chung HC
    J Glob Oncol; 2018 Jul; 4():1-12. PubMed ID: 30085888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence and risk of hypertension with ramucirumab in cancer patients: a meta-analysis of published studies.
    Wang J; Wang Z; Zhao Y
    Clin Drug Investig; 2015 Apr; 35(4):221-8. PubMed ID: 25697774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials.
    Ranpura V; Hapani S; Chuang J; Wu S
    Acta Oncol; 2010 Apr; 49(3):287-97. PubMed ID: 20156114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hematologic toxicities associated with mTOR inhibitors temsirolimus and everolimus in cancer patients: a systematic review and meta-analysis.
    Xu J; Tian D
    Curr Med Res Opin; 2014 Jan; 30(1):67-74. PubMed ID: 24028709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis.
    Ranpura V; Hapani S; Wu S
    JAMA; 2011 Feb; 305(5):487-94. PubMed ID: 21285426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paclitaxel-based versus docetaxel-based regimens in metastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials.
    Qi WX; Shen Z; Lin F; Sun YJ; Min DL; Tang LN; He AN; Yao Y
    Curr Med Res Opin; 2013 Feb; 29(2):117-25. PubMed ID: 23216340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.